These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 37552603)
21. Receptor tyrosine kinase-like orphan receptor 2 (Ror2) expression creates a poised state of Wnt signaling in renal cancer. Rasmussen NR; Wright TM; Brooks SA; Hacker KE; Debebe Z; Sendor AB; Walker MP; Major MB; Green J; Wahl GM; Rathmell WK J Biol Chem; 2013 Sep; 288(36):26301-26310. PubMed ID: 23893409 [TBL] [Abstract][Full Text] [Related]
22. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201 [TBL] [Abstract][Full Text] [Related]
23. A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells. Hessenkemper W; Roediger J; Bartsch S; Houtsmuller AB; van Royen ME; Petersen I; Grimm MO; Baniahmad A Mol Endocrinol; 2014 Nov; 28(11):1831-40. PubMed ID: 25203674 [TBL] [Abstract][Full Text] [Related]
24. hASH1 nuclear localization persists in neuroendocrine transdifferentiated prostate cancer cells, even upon reintroduction of androgen. Fraser JA; Sutton JE; Tazayoni S; Bruce I; Poole AV Sci Rep; 2019 Dec; 9(1):19076. PubMed ID: 31836808 [TBL] [Abstract][Full Text] [Related]
25. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes. Axlund SD; Lambert JR; Nordeen SK Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772 [TBL] [Abstract][Full Text] [Related]
26. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review. Kono M; Fujii T; Lim B; Karuturi MS; Tripathy D; Ueno NT JAMA Oncol; 2017 Sep; 3(9):1266-1273. PubMed ID: 28301631 [TBL] [Abstract][Full Text] [Related]
29. An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Davies A; Nouruzi S; Ganguli D; Namekawa T; Thaper D; Linder S; Karaoğlanoğlu F; Omur ME; Kim S; Kobelev M; Kumar S; Sivak O; Bostock C; Bishop J; Hoogstraat M; Talal A; Stelloo S; van der Poel H; Bergman AM; Ahmed M; Fazli L; Huang H; Tilley W; Goodrich D; Feng FY; Gleave M; He HH; Hach F; Zwart W; Beltran H; Selth L; Zoubeidi A Nat Cell Biol; 2021 Sep; 23(9):1023-1034. PubMed ID: 34489572 [TBL] [Abstract][Full Text] [Related]
30. ROR2 suppresses metastasis of prostate cancer via regulation of miR-199a-5p-PIAS3-AKT2 signaling axis. Tseng JC; Huang SH; Lin CY; Wang BJ; Huang SF; Shen YY; Chuu CP Cell Death Dis; 2020 May; 11(5):376. PubMed ID: 32415173 [TBL] [Abstract][Full Text] [Related]
31. Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain. Hua Y; Azeem W; Shen Y; Zhang S; Olsen JR; Øyan AM; Ke X; Zhang W; Kalland KH Pharmacol Res Perspect; 2018 Dec; 6(6):e00437. PubMed ID: 30410767 [TBL] [Abstract][Full Text] [Related]
32. Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder. Tyagi A; Chandrasekaran B; Kolluru V; Rai S; Jordan AC; Houda A; Messer J; Ankem M; Damodaran C; Haddad A Urol Oncol; 2019 Jul; 37(7):492-502. PubMed ID: 31006613 [TBL] [Abstract][Full Text] [Related]
33. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. Graham L; Schweizer MT Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852 [TBL] [Abstract][Full Text] [Related]
34. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer. Pilling A; Kim SH; Hwang C Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379 [TBL] [Abstract][Full Text] [Related]
35. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer. Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193 [TBL] [Abstract][Full Text] [Related]
36. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Chatterjee B Mol Cell Biochem; 2003 Nov; 253(1-2):89-101. PubMed ID: 14619959 [TBL] [Abstract][Full Text] [Related]
37. Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness. Little GH; Baniwal SK; Adisetiyo H; Groshen S; Chimge NO; Kim SY; Khalid O; Hawes D; Jones JO; Pinski J; Schones DE; Frenkel B Cancer Res; 2014 May; 74(10):2857-68. PubMed ID: 24648349 [TBL] [Abstract][Full Text] [Related]
38. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution. Imamura J; Ganguly S; Muskara A; Liao RS; Nguyen JK; Weight C; Wee CE; Gupta S; Mian OY Front Endocrinol (Lausanne); 2023; 14():1191311. PubMed ID: 37455903 [TBL] [Abstract][Full Text] [Related]
39. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. Kregel S; Kiriluk KJ; Rosen AM; Cai Y; Reyes EE; Otto KB; Tom W; Paner GP; Szmulewitz RZ; Vander Griend DJ PLoS One; 2013; 8(1):e53701. PubMed ID: 23326489 [TBL] [Abstract][Full Text] [Related]
40. Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells. Chen M; Feuerstein MA; Levina E; Baghel PS; Carkner RD; Tanner MJ; Shtutman M; Vacherot F; Terry S; de la Taille A; Buttyan R Mol Cancer; 2010 Apr; 9():89. PubMed ID: 20420697 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]